What We Offer
- Formulation, optimization, lead selection: design and production of nanoformulations to achieve intended biological endpoints. Our staff has experience with small molecules, biologics, vaccines, and gene therapies.
- Mechanistic studies: in vitro and in vivo studies to identify pharmacological or toxicological mechanisms.
- Non-oncology nanomaterials: nanomedicines for other therapeutic indications; environmental, health, and safety characterization of engineered nanomaterials, etc.
- Bioanalytical assay development: development and validation of assays for lot release, biological activity, bioequivalence, and more.
- Instrument optimization: NCL works with instrument developers to improve analytical tools to best meet the needs of the nanotech research community.
- And more… Contact us at ncl@mail.nih.gov to see how we can help.
cCRADA Process
cCRADA candidate projects are considered on a case-by-case basis throughout the year. We take several criteria into consideration, including optimal use of NCL’s capabilities and resources and alignment with NCL and NCI’s research interests. We also weigh a project's potential impact to improve nanomedicine research and development. Interested parties can email the NCL (ncl@mail.nih.gov) to discuss their project needs.
For approved projects, work is initiated through a cCRADA with Leidos Biomedical Research, Inc., the operations and technical support contractor for the Frederick National Lab.